Technology

Sesen Bio

$1.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+1.87%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Sesen Bio and other stocks, options, and ETFs commission-free!

About SESN

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. The listed name for SESN is Sesen Bio, Inc. Common Stock.

CEO
Thomas R. Cannell
Employees
25
Headquarters
Cambridge, Massachusetts
Founded
2008
Market Cap
210.82M
Price-Earnings Ratio
Dividend Yield
Average Volume
4.60M
High Today
$1.80
Low Today
$1.56
Open Price
$1.74
Volume
5.93M
52 Week High
$1.82
52 Week Low
$0.37

Collections

SESN Earnings

-$0.67
-$0.34
-$0.02
$0.31
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

GTH
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure